Embla Medical hf: Embla Medical closes the majority share investment in Streifeneder ortho.production GmbH
Embla Medical (NASDAQ Copenhagen: EMBLA) has successfully completed its majority share acquisition of Streifeneder ortho.production GmbH, now owning 51% of the company. Streifeneder, an international developer of orthopaedic mobility solutions with approximately 100 employees, reported sales of EUR 25 million in 2024, with 70% derived from prosthetics and orthopaedic materials.
To facilitate the transaction, Embla Medical's Board has issued 2,805,135 new shares at DKK 33.26 per share, increasing the company's nominal share capital by 0.7% to ISK 430,441,257. The total value of the share capital increase amounts to DKK 93 million (EUR 12.5 million). The sellers have agreed to a two-year lock-up period for the new shares.
The transaction is not expected to materially impact Embla Medical's 2025 financial guidance.Embla Medical (NASDAQ Copenhagen: EMBLA) ha completato con successo l'acquisizione della quota di maggioranza di Streifeneder ortho.production GmbH, detenendone ora il 51%. Streifeneder, sviluppatore internazionale di soluzioni per la mobilit脿 ortopedica con circa 100 dipendenti, ha registrato nel 2024 ricavi di EUR 25 milioni, di cui il 70% derivante da protesi e materiali ortopedici.
Per finanziare l'operazione, il Consiglio di amministrazione di Embla Medical ha emesso 2.805.135 nuove azioni al prezzo di DKK 33,26 per azione, incrementando il capitale sociale nominale dello 0,7% fino a ISK 430.441.257. Il valore totale dell'aumento di capitale 猫 di DKK 93 milioni (EUR 12,5 milioni). I venditori hanno accettato un periodo di lock-up di due anni sulle nuove azioni.
L'operazione non dovrebbe avere un impatto significativo sulle previsioni finanziarie di Embla Medical per il 2025.
Embla Medical (NASDAQ Copenhagen: EMBLA) ha completado con 茅xito la adquisici贸n de la participaci贸n mayoritaria de Streifeneder ortho.production GmbH, poseyendo ahora el 51% de la compa帽铆a. Streifeneder, desarrollador internacional de soluciones de movilidad ortop茅dica con aproximadamente 100 empleados, registr贸 ventas de EUR 25 millones en 2024, de las cuales el 70% provino de pr贸tesis y materiales ortop茅dicos.
Para facilitar la transacci贸n, la Junta de Embla Medical emiti贸 2.805.135 nuevas acciones a DKK 33,26 por acci贸n, aumentando el capital social nominal en un 0,7% hasta ISK 430.441.257. El valor total del aumento de capital asciende a DKK 93 millones (EUR 12,5 millones). Los vendedores han aceptado un periodo de bloqueo (lock-up) de dos a帽os para las nuevas acciones.
Se espera que la transacci贸n no afecte materialmente a la gu铆a financiera de Embla Medical para 2025.
Embla Medical (NASDAQ Copenhagen: EMBLA)电� Streifeneder ortho.production GmbH鞚� 瓿茧皹靾� 歆�攵� 鞚胳垬毳� 靹标车鞝侅溂搿� 鞕勲頃橃棳 順勳灛 頃措嫻 須岇偓鞚� 51%毳� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞎� 100氇呾潣 歆侅洂鞚� 霊� 鞝曧槙鞕戈臣 鞚措彊靹� 靻旊（靺橃潣 甑牅鞝� 臧滊皽鞐呾泊鞚� Streifeneder电� 2024雲� 毵れ稖 EUR 2,500毵�鞚� 氤搓碃頄堨溂氅�, 攴� 欷� 70%电� 鞚橃垬路氤挫“旮� 氚� 鞝曧槙鞕戈臣 鞛愳灛鞐愳劀 氚滌儩頄堨姷雼堧嫟.
瓯半灅毳� 鞙勴暣 Embla Medical 鞚挫偓須尩鐢 欤茧嫻 DKK 33.26鞐� 2,805,135欤�鞚� 鞁犾＜毳� 氚滍枆頃橃棳 氇呺鞛愲掣旮堨潉 0.7% 歃濌皜鞁滌紲 ISK 430,441,257搿� 毵岆摛鞐堨姷雼堧嫟. 歃濎瀽 攴滊电� 齑� DKK 9,300毵� (EUR 1,250毵�)鞛呺媹雼�. 毵る弰鞛愲摛鞚� 鞁犾＜鞐� 雽�頃� 2雲勱皠 霛届梾 旮瓣皠鞐� 霃欖潣頄堨姷雼堧嫟.
鞚措矆 瓯半灅电� Embla Medical鞚� 2025雲� 鞛 臧�鞚措崢鞀れ棎 欷戨寑頃� 鞓來枼鞚� 氙胳箻歆� 鞎婌潉 瓴冹溂搿� 鞓堨儊霅╇媹雼�.
Embla Medical (NASDAQ Copenhagen: EMBLA) a finalis茅 avec succ猫s l'acquisition de la participation majoritaire de Streifeneder ortho.production GmbH, d茅tenant d茅sormais 51 % de la soci茅t茅. Streifeneder, d茅veloppeur international de solutions de mobilit茅 orthop茅dique employant environ 100 personnes, a d茅clar茅 un chiffre d'affaires de 25 M鈧� en 2024, dont 70 % proviennent des proth猫ses et des mat茅riaux orthop茅diques.
Pour faciliter la transaction, le conseil d'administration d'Embla Medical a 茅mis 2 805 135 nouvelles actions au prix de DKK 33,26 par action, augmentant le capital social nominal de 0,7 % pour atteindre ISK 430 441 257. La valeur totale de l'augmentation de capital s'茅l猫ve 脿 DKK 93 millions (EUR 12,5 millions). Les vendeurs ont accept茅 une p茅riode de blocage (lock-up) de deux ans pour les nouvelles actions.
La transaction ne devrait pas avoir d'impact significatif sur les pr茅visions financi猫res d'Embla Medical pour 2025.
Embla Medical (NASDAQ Copenhagen: EMBLA) hat die Mehrheitsbeteiligung an der Streifeneder ortho.production GmbH erfolgreich abgeschlossen und h盲lt nun 51 % des Unternehmens. Streifeneder, ein internationaler Entwickler orthop盲discher Mobilit盲tsl枚sungen mit rund 100 Mitarbeitern, meldete f眉r 2024 einen Umsatz von EUR 25 Millionen, davon 70 % aus Prothesen und orthop盲dischen Materialien.
Zur Abwicklung der Transaktion hat der Vorstand von Embla Medical 2.805.135 neue Aktien zu je DKK 33,26 ausgegeben und das nominale Grundkapital um 0,7 % auf ISK 430.441.257 erh枚ht. Der Gesamtwert der Kapitalerh枚hung bel盲uft sich auf DKK 93 Millionen (EUR 12,5 Millionen). Die Verk盲ufer haben einer zweij盲hrigen Sperrfrist (Lock-up) f眉r die neuen Aktien zugestimmt.
Die Transaktion wird voraussichtlich keine wesentlichen Auswirkungen auf die Finanzprognose von Embla Medical f眉r 2025 haben.
- Strategic acquisition of 51% stake in Streifeneder expands Embla's orthopaedic mobility solutions portfolio
- Streifeneder generates significant revenue of EUR 25 million (2024) with 70% from prosthetics and orthopaedic materials
- Sellers commit to long-term alignment with a two-year lock-up period on newly issued shares
- Minimal share dilution of only 0.7% from the transaction
- Share capital increase of DKK 93 million through new share issuance
- No immediate material positive impact expected on 2025 financial guidance
Insights
Embla Medical's 51% acquisition of Streifeneder strengthens its orthopedic portfolio but has minimal immediate financial impact.
Embla Medical has officially completed its 51% majority stake acquisition in Streifeneder ortho.production, a strategic move that expands its orthopedic mobility solutions portfolio. Streifeneder brings approximately
The transaction structure reveals thoughtful financial engineering. Embla issued 2,805,135 new shares at
While the company states the transaction won't materially impact 2025 financial guidance, this acquisition has strategic significance. It gives Embla immediate access to Streifeneder's specialized product lines and approximately 100 employees with expertise in prosthetic components, orthotic solutions, and orthopedic materials. This controlled expansion allows Embla to enhance its competitive position in the orthopedic mobility market without significantly altering its near-term financial trajectory.
Announcement no. 39/2025
29 August 2025听
Reference is made to announcement no. 31/2025 published on 17 July 2025 (Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH).
Streifeneder ortho.production is an international developer and supplier of orthopaedic mobility solutions, employing around 100 people. In addition to its offerings of prosthetic and orthotic components, Streifeneder ortho.production also supplies orthopaedic materials and equipment to the O&P industry. In 2024, Streifeneder ortho.production realized sales of
In connection with the investment, the Board of Directors of Embla Medical has resolved to utilize the authorization in Article 5, paragraph 1, of the Articles of Association to issue 2,805,135 new shares in Embla Medical, raising the total share capital in nominal value by
The sellers of Streifeneder ortho.production will subscribe for all the new shares. The sellers have also agreed to a two-year lock-up period from closing for all the new shares.
The transaction is not expected to have any material impact on the financial guidance for 2025.
Further information Embla Medical
Klaus Sindahl
Head of Investor Relations
M: +45 5363 0134
E: [email protected]听
Edda Heidrun Geirsdottir
VP of Corporate Communication
M: +354 664 1055
E: [email protected]听
Further information Streifeneder
Sabine Knobloch
Head of Legal Department
M: +49 172 8165265
E: [email protected]听
Embla Medical press releases by e-mail
If you wish to receive Embla Medical press releases by e-mail, please register at
About Embla Medical
Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in
Embla Medical was formerly listed as 脰ssur (OSSR) on Nasdaq Copenhagen until 8 April 2024.
This information was brought to you by Cision
The following files are available for download:
| 20250829 Embla Medical closes the majoriy share investment in Steifeneder ortho.production GmbH FINAL |
听
View original content:
SOURCE Embla Medical hf.
FAQ
What percentage stake did Embla Medical acquire in Streifeneder ortho.production?
How much revenue did Streifeneder ortho.production generate in 2024?
How many new shares did Embla Medical issue for the Streifeneder acquisition?
What is the lock-up period for the newly issued Embla Medical shares?
How will the Streifeneder acquisition affect Embla Medical's 2025 financial guidance?
